Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A $63m VC Round Takes E-Scape Into Clinic With Alzheimer's, Parkinson's Drugs

Executive Summary

E-Scape's Series A cash will fund the development of small molecules targeting genetic drivers of neurodegenerative diseases, such as ApoE4 in Alzheimer's disease. The venture capital financing with big pharma backing will be used to take two programs into the clinic.

You may also be interested in...



Accera Posts Phase III Alzheimer's Failure, But Moves Ahead With New Formulation

Accera blamed the study's failure on a revised formulation for AC-1204, but the company plans to begin a second Phase III trial with an improved formulation of the drug in the second or third quarter of 2017.

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.

Alzheon's Reclaimed Alzheimer's Drug Has Potential To Win Big – If History Doesn't Repeat

New data for Alzheon's Alzheimer's disease drug, tramiprosate, from two Phase III trials that failed to show efficacy in 2007 may shed light on how the company can better design new trials for follow-on product ALZ-801, for which it will initiate pivotal Phase III studies next year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel